Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9.
Christen F, Hablesreiter R, Hoyer K, Hennch C, Maluck-Böttcher A, Segler A, Madadi A, Frick M, Bullinger L, Briest F, Damm F. Christen F, et al. Among authors: briest f. Leukemia. 2022 Apr;36(4):1102-1110. doi: 10.1038/s41375-021-01469-x. Epub 2021 Nov 15. Leukemia. 2022. PMID: 34782715 Free PMC article.
FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
Briest F, Berg E, Grass I, Freitag H, Kaemmerer D, Lewens F, Christen F, Arsenic R, Altendorf-Hofmann A, Kunze A, Sänger J, Knösel T, Siegmund B, Hummel M, Grabowski P. Briest F, et al. Oncotarget. 2015 Apr 10;6(10):8185-99. doi: 10.18632/oncotarget.3600. Oncotarget. 2015. PMID: 25797272 Free PMC article.
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Taromi S, Lewens F, Arsenic R, Sedding D, Sänger J, Kunze A, Möbs M, Benecke J, Freitag H, Christen F, Kaemmerer D, Lupp A, Heilmann M, Lammert H, Schneider CP, Richter K, Hummel M, Siegmund B, Burger M, Briest F, Grabowski P. Taromi S, et al. Among authors: briest f. Oncotarget. 2017 Sep 23;8(57):97061-97078. doi: 10.18632/oncotarget.21221. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228593 Free PMC article.
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K, Hablesreiter R, Inoue Y, Yoshida K, Briest F, Christen F, Kakiuchi N, Yoshizato T, Shiozawa Y, Shiraishi Y, Striefler JK, Bischoff S, Lohneis P, Putter H, Blau O, Keilholz U, Bullinger L, Pelzer U, Hummel M, Riess H, Ogawa S, Sinn M, Damm F. Hoyer K, et al. Among authors: briest f. EBioMedicine. 2021 Apr;66:103327. doi: 10.1016/j.ebiom.2021.103327. Epub 2021 Apr 13. EBioMedicine. 2021. PMID: 33862582 Free PMC article. Clinical Trial.
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
Briest F, Noerenberg D, Hennch C, Yoshida K, Hablesreiter R, Nimo J, Sasca D, Kirchner M, Mansouri L, Inoue Y, Wiegand L, Staiger AM, Casadei B, Korkolopoulou P, Weiner J, Lopez-Guillermo A, Warth A, Schneider T, Nagy Á, Klapper W, Hummel M, Kanellis G, Anagnostopoulos I, Mertins P, Bullinger L, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Briest F, et al. Leukemia. 2023 Nov;37(11):2237-2249. doi: 10.1038/s41375-023-02013-9. Epub 2023 Aug 30. Leukemia. 2023. PMID: 37648814 Free PMC article.
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, Ueno H, Staiger AM, Ziepert M, Asmar F, Locher BN, Toth E, Weber T, Amini RM, Klapper W, Bouzani M, Poeschel V, Rosenwald A, Held G, Campo E, Ishaque N, Stamatopoulos K, Kanellis G, Anagnostopoulos I, Bullinger L, Goldschmidt N, Zinzani PL, Bödör C, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Noerenberg D, et al. Among authors: briest f. J Clin Oncol. 2024 Feb 1;42(4):452-466. doi: 10.1200/JCO.23.01053. Epub 2023 Dec 6. J Clin Oncol. 2024. PMID: 38055913
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
Briest F, Grass I, Sedding D, Möbs M, Christen F, Benecke J, Fuchs K, Mende S, Kaemmerer D, Sänger J, Kunze A, Geisler C, Freitag H, Lewens F, Worpenberg L, Iwaszkiewicz S, Siegmund B, Walther W, Hummel M, Grabowski P. Briest F, et al. Neuroendocrinology. 2018;107(1):1-23. doi: 10.1159/000481506. Epub 2017 Sep 14. Neuroendocrinology. 2018. PMID: 28910819
Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.
Briest F, Koziolek EJ, Albrecht J, Schmidt F, Bernsen MR, Haeck J, Kühl AA, Sedding D, Hartung T, Exner S, Welzel M, Fischer C, Grötzinger C, Brenner W, Baum RP, Grabowski P. Briest F, et al. Neoplasia. 2021 Jan;23(1):80-98. doi: 10.1016/j.neo.2020.11.004. Epub 2020 Nov 25. Neoplasia. 2021. PMID: 33246310 Free PMC article.
Vandetanib therapy in medullary thyroid cancer.
Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D. Grabowski P, et al. Among authors: briest f. Drugs Today (Barc). 2012 Nov;48(11):723-33. doi: 10.1358/dot.2012.48.11.1867323. Drugs Today (Barc). 2012. PMID: 23170308 Review.
17 results